FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086595413> ?p ?o ?g. }

• W2086595413 endingPage "433" @default.
• W2086595413 startingPage "433" @default.
• W2086595413 abstract "Background: Recombinant human growth hormone (GH) has been available since 1986 for the treatment of short stature but there is a paucity of final height data. Aims: The aims of this study were to determine the final height achieved following GH therapy under Australian dosage schedules at a single centre. Methods: Selection criteria included GH therapy commenced after 1985 and a diagnosis of familial short stature, maturational delay, idiopathic short stature (collectively non-GHD), GH deficiency, intrauterine growth retardation (IUGR), Turner syndrome (TS), Russell Silver syndrome (RS) or Noonan syndrome (NS). Growth hormone deficient patients were further divided into congenital/idiopathic (GHD) and those secondary to childhood cancer (GHD-onc). Non-GHD patients were also subdivided into those with a bone age delay of >2 years (non-GHD-delay) or appropriate bone age (non-GHD). Final height was defined at (1) a bone age >17 years (male) or >15 years (female), (2) males >18 years or females >16 years with a growth velocity <2 cm/year, or (3) patients >30 years of age with a recent height measurement. Results: Final height was available for 428 patients. Mean age at start of treatment was 10.9 years and mean duration of treatment was 4.7 years for all groups. Median starting dose of GH was the same for all groups (5.0 mg/m2/week) apart from TS (8.6 mg/m2/week). Similarly, median final dose was 7.3 mg/m2/week for all groups apart from TS (9 mg/m2/week). GHD-onc patients started GH at a higher start height SDS compared to other patients. GHD patients had a better first year response to GH compared to other patients and achieved a higher final height SDS. They were also closer to their mid parental height (MPH). Despite having similar first year responses, patients with IUGR and RS had the lowest overall response to GH therapy. Regression analysis showed that the first year response to GH and commencement before puberty were associated with better final height responses in all patient groups. Conclusion: Final height outcomes were significantly lower than target heights (MPH) for all groups. Clinical Implications: These results highlight the need for ongoing evaluation of GH dose and duration. Endocrine nurses are pivotal in this process." @default.
• W2086595413 created "2016-06-24" @default.
• W2086595413 creator A5016105993 @default.
• W2086595413 creator A5022008789 @default.
• W2086595413 creator A5022171301 @default.
• W2086595413 creator A5045841376 @default.
• W2086595413 creator A5060024617 @default.
• W2086595413 creator A5063477608 @default.
• W2086595413 creator A5088851557 @default.
• W2086595413 date "2015-03-01" @default.
• W2086595413 modified "2023-09-25" @default.
• W2086595413 title "020–Final Height Outcome Following Growth Hormone: The Australian Experience" @default.
• W2086595413 doi "https://doi.org/10.1016/j.pedn.2015.01.017" @default.
• W2086595413 hasPublicationYear "2015" @default.
• W2086595413 type Work @default.
• W2086595413 sameAs 2086595413 @default.
• W2086595413 citedByCount "0" @default.
• W2086595413 crossrefType "journal-article" @default.
• W2086595413 hasAuthorship W2086595413A5016105993 @default.
• W2086595413 hasAuthorship W2086595413A5022008789 @default.
• W2086595413 hasAuthorship W2086595413A5022171301 @default.
• W2086595413 hasAuthorship W2086595413A5045841376 @default.
• W2086595413 hasAuthorship W2086595413A5060024617 @default.
• W2086595413 hasAuthorship W2086595413A5063477608 @default.
• W2086595413 hasAuthorship W2086595413A5088851557 @default.
• W2086595413 hasBestOaLocation W20865954131 @default.
• W2086595413 hasConcept C126322002 @default.
• W2086595413 hasConcept C187212893 @default.
• W2086595413 hasConcept C2776149932 @default.
• W2086595413 hasConcept C2777871287 @default.
• W2086595413 hasConcept C2778754045 @default.
• W2086595413 hasConcept C2779683239 @default.
• W2086595413 hasConcept C2779952775 @default.
• W2086595413 hasConcept C2910005497 @default.
• W2086595413 hasConcept C2984496839 @default.
• W2086595413 hasConcept C71315377 @default.
• W2086595413 hasConcept C71924100 @default.
• W2086595413 hasConcept C89551170 @default.
• W2086595413 hasConceptScore W2086595413C126322002 @default.
• W2086595413 hasConceptScore W2086595413C187212893 @default.
• W2086595413 hasConceptScore W2086595413C2776149932 @default.
• W2086595413 hasConceptScore W2086595413C2777871287 @default.
• W2086595413 hasConceptScore W2086595413C2778754045 @default.
• W2086595413 hasConceptScore W2086595413C2779683239 @default.
• W2086595413 hasConceptScore W2086595413C2779952775 @default.
• W2086595413 hasConceptScore W2086595413C2910005497 @default.
• W2086595413 hasConceptScore W2086595413C2984496839 @default.
• W2086595413 hasConceptScore W2086595413C71315377 @default.
• W2086595413 hasConceptScore W2086595413C71924100 @default.
• W2086595413 hasConceptScore W2086595413C89551170 @default.
• W2086595413 hasIssue "2" @default.
• W2086595413 hasLocation W20865954131 @default.
• W2086595413 hasOpenAccess W2086595413 @default.
• W2086595413 hasPrimaryLocation W20865954131 @default.
• W2086595413 hasRelatedWork W2082262725 @default.
• W2086595413 hasRelatedWork W2086595413 @default.
• W2086595413 hasRelatedWork W2093442803 @default.
• W2086595413 hasRelatedWork W2163193485 @default.
• W2086595413 hasRelatedWork W2297896522 @default.
• W2086595413 hasRelatedWork W2387550679 @default.
• W2086595413 hasRelatedWork W2396202742 @default.
• W2086595413 hasRelatedWork W2416473018 @default.
• W2086595413 hasRelatedWork W2959060571 @default.
• W2086595413 hasRelatedWork W4238961491 @default.
• W2086595413 hasVolume "30" @default.
• W2086595413 isParatext "false" @default.
• W2086595413 isRetracted "false" @default.
• W2086595413 magId "2086595413" @default.
• W2086595413 workType "article" @default.